Single dose oral lumiracoxib for postoperative pain

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Roy, Yvonne M ^a   Derry, S ^b   Moore, R A ^b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Administration, oral; Cyclooxygenase 2 inhibitors *administration dosage ; Diclofenac administration dosage; *analogs derivatives ; Humans; Pain, postoperative *drug therapy ; Randomized controlled trials as topic

Indexed keywords

IBUPROFEN; LUMIRACOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ANALGESIA; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECT; GASTROINTESTINAL SYMPTOM; HUMAN; POSTOPERATIVE PAIN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

EID: 44949249075     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006865     Document Type: Review

References (44)

1. Chan 2005 {published data only} Chan VWS, Clark A J, Davis JC, Wolf RS, Kellstein D, Jayawardene S. The post-operative analgesic efficacy and tolerability of lumiracoxib compared with placebo and naproxen after total knee or hip arthroplasty. Acta Anaesthesiologica Scandinavica 2005;Nov 49(10):1491-500.
2. Kellstein 2004 {published data only} Kellstein D, Ott D, Jayawardene S, Fricke J. Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. International Journal of Clinical Practice 2004;58(3):244-50.
3. Zelenakas 2004 {published data only} Zelenakas K, Fricke JR Jr, Jayawardene S, Kellstein D. Analgesic efficacy of single oral doses of lumiracoxib and ibuprofen in patients with postoperative dental pain. International Journal of Clinical Practice 2004;58(3):251-6.
4. Bitner 2004 Bitner M, Katterhorn J, Hatfield C, Gao J, Kellstein D. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. International Journal Clinical Practice 2004;58(4):340-5.
5. Schnitzer 2004 Schnitzer TJ, Beier J, Geusens P, Hasler P, Patel SK, Senftleber I, et al.Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four week, multicenter randomised, double blind, placebo-controlled trial. Arthritis and Rheumatism 2004;51(4):549-57.
6. Lumiracoxib(a) Novartis Pharmaceuticals. Efficacy of lumiracoxib in relieving moderate to severe post-dental pain, compared to both placebo and celecoxib. www.controlled-trials.com/mrct/trial/printfriendly/179985.
7. Lumiracoxib(b) Novartis Pharmaceuticals. Efficacy and safety of lumiracoxib in arthroscopic knee surgery. www.controlled-trials.com/mrct/ trialprintfriendly/177605.
8. Adebayo 2006 Adebayo D, Bjarnason I. Is non-steroidal anti-inflammatory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?. Post Graduate Medical Journal 2006;82(965):186-91.
9. Bandolier 2007 Bandolier Acute Pain Analgesic League Table. http://www.jr2.ox.ac.uk/Bandolier/booth/painpag/Acutrev/Analgesics/Leagtab.html (accessed March 2007).
10. Bannwarth 2005 Bannworth B, Berenbaum F. Clinical pharmacology of lumiracoxib, a second generation cyclooxygenase 2 selective inhibitor. Expert Opinion on Investigational Drugs 2005;14(4):521-33.
11. Barden 2004 Barden J, Edwards JE, McQuay HJ, Moore RA. Pain and analgesic response after third molar extraction and other postsurgical pain. Pain 2004;107:86-90.
12. Benson 2000 Benson WG, Zhao SZ, Burke TA, Zabinski RA, Makuch RW, Maurauth CJ, et al.Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. Journal of Rheumatology 2000;27:1876-83.
13. Bruster 1994 Bruster S, Jarman B, Bosanquet N, Weston D, Erens R, Delbanco TL, et al.National Survey of Hospital Patients. BMJ 1994;309(6968):1542-6.
14. Cook 1995 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310:452-4.
15. Cooper 1991 Cooper SA. Single-dose analgesic studies: the upside and downside of assay sensitivity. In: MaxMB, PortenoyRK, LaskaEM editor(s). The design of analgesic clinical trials. Advances in Pain Research and Therapy. Vol. 18, New York: Raven Press, 1991:117-24.
16. Day 1988 Day RO, McLachlan AJ, Graham GG, Williams KM. Pharmokinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Baillieres Clinical Rheumatology 1988;2:363-93.
17. Edwards 1999 Edwards JE, McQuay HJ, Moore A, Collins SL. Reporting of adverse effects in clinical trials should be improved: Lessons from acute postoperative pain. Journal of Pain and Symptom Management 1999;18(6):427-37.
18. Edwards 2004 Edwards JE, Moore RA, McQuay HJ. Individual patient analysis of single-dose rofecoxib in postoperative pain. BMC Antesthesiology 2004;4(3):1-10.
19. Eypasch 1995 Eypasch E, Lefering R, Kum CK, Troidl H. Probability of adverse events that have not yet occurred: a statistical reminder. BMJ 1995;311:619-20.
20. Fortun 2005 Fortun PJ, Hawkey CJ. Nonsteroidal antiinflammatory drugs and the small intestine. Current Opinion in Gastroenterology 2005;21(2):169-75.
21. GarciaRodriguez 2003 Garcia Rodriguez LA, Hernandez-Diaz S. Non-steroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology 2003;14:240-6.
22. Griffin 2000 Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflamatory drugs and acute renal failure in elderly persons. American Journal of Epidemiology 2000;151:488-96.
23. Henry 1997 Henry D, Page J, Whyte I, Nanra R, Hall C. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. British Journal of Clinical Pharmacology 1997;44:85-90.
24. Hernandez-Diaz 2000 Hernández-Diaz S, García Rodriguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding and perforation: An overview of epidemiological studies published in the 1990s. Archives of Internal Medicine 2000;160:2093-9.
25. Hernandez-Diaz 2006 Hernandez-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clinical Pharmacology and Toxicology 2006;98(3):266-74.
26. Jadad 1996b Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, et al.Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
27. Kearney 2006 Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006;332:1302-08.
28. Laine 2006 Laine L, Smith R, Min K, Chen C, Dubois RW. Systematic review: the lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs. Alimentary Pharmacology and Therapeutics 2006;Sep 24(5):751-67.
29. McGettigan 2006 McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296(13):1633-44.
30. Moore 1996 Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics. Pain 1996;66(2-3):229-37.
31. Moore 1997a Moore A, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Verification from independent data. Pain 1997;69(1-2): 127-30.
32. Moore 1997b Moore A, Moore O, McQuay H, Gavaghan D. Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics: Use of pain intensity and visual analogue scales. Pain 1997;69(3):311-5.
33. Moore 1998 Moore RA, Gavaghan D, Tramer MR, Collins SL, McQuay HJ. Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209-16.
34. Moore 2005 Moore RA, Edwards JE, McQuay HJM. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain 2005;116:322-31.
35. Morris 1995 Morris JA, Gardner MJ. Calculating confidence intervals for relative risk, odds ratio and standardised ratios and rates. In: GardnerMJ, AltmanDG editor(s). Statistics with confidence - confidence intervals and statistical guidelines. London: BMJ, 1995:50-63.
36. Mysler 2004 Mysler E. Lumiracoxib (Prexige): a new selective COX-2 inhibitor. International Journal of Clinical Practice 2004;58(6):606-11.
37. Nussmeier 2005 Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al.Complications of the Cox-2 inhibitors parecoxib and valdecoxib after cardiac surgery. New England Journal of Medicine 2005;352(11):1081-91.
38. Nussmeier 2006 Nussmeier NA, Whelton AA, Brown MT, Joshi G, Langford RM, Singla NK, et al.Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after non-cardiac surgery. Anesthesiology 2006;104(3):518-26.
39. Ott 2003 Ott E, Nussmeier NA, Duke PC, Feneck RO, Alston RP, Snabes MC, et al.Efficacy and safety of the cylooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. Journal of Thoracic and Cardiovascular Surgery 2003;125(6):1481- 92.
40. Page 2000 Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: An underrecognized public health problem. Archives of Internal Medicine 2000;160:777- 84.
41. Scheiman 2005 Scheiman JM, Fendrick MA. Practical approaches to minimizing gastrointestinal and cardiovascular safety conerns with COX-2 inhibitors and NSAIDs. Arthritis Research & Therapy 2005;7 (suppl 4):S23-S29.
42. Schnitzer 2004a Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, et al.Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004;364(9435):665-74.
43. Smith 2001 Smith LA, Moore RA, McQuay H, Gavaghan D. Using evidence from different sources: an example using paracetamol 1000 mg plus codeine 60 mg. BMC Medical Research Methodology 2001;1:1.
44. Vestergaard 2006 Vestergaard P, Rejnmark L, Mosekilde L. Fracture risk associated with use of nonsteroidal anti-inflammatory drugs, acetylsalicylic acid, and acetaminophen and the effects of rheumatoid arthritis and osteoarthritis. Calcified Tissue International 2006;79(2):84- 94.